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INTRODUCTION
Published studies from our laboratory have shown that critical mediators of tumor cell physiology and behavior reside in cholesterol-rich, lipid raft membranes of prostate cancer cells. This project focuses on the RNA binding protein heterogeneous nuclear ribonucleoprotein K (hnRNP-K) as a novel regulator of the androgen receptor (AR). We have found that hnRNP-K lies within the cholesterolsensitive PI3K/Akt/PTEN/mTOR pathway and that hnRNP-K connects ErbB receptor/Akt-derived signals with androgenic signals, thereby directly linking peptide hormone and steroid hormone signal transduction mechanisms. Our hypothesis is that hnRNP-K mediates androgen sensitivity and growth and survival in prostate cancer cells by a mechanism involving the regulation of AR mRNA translation. The specific aims are: Aim 1. Determine the mechanism(s) underlying the effects of hnRNP-K on androgen sensitivity in prostate cancer cells. Aim 2. Determine whether changes in expression and/or subcellular localization alter the function of hnRNP-K and assess the physiologic consequences of these changes in prostate cancer cells. HnRNP-K has been shown to be regulate translation of a number of mRNAs and the protein lies downstream from the EGFR in some contexts. Consequently, hnRNP-K is a logical intermediate in a pathway we previously described leading from EGFR to mTOR, in which AR protein levels are downregulated at the level of mRNA translation [1] .
To test the potential involvement of hnRNP-K in this mechanism, we first examined the effect of hnRNP-K on AR expression in LNCaP cells. Enforced expression of hnRNP-K lowered AR protein levels in both the presence and absence of the synthetic androgen, R1881 (1nM), without any effect on the levels of the signaling receptors EGFR and KDR, or on β-actin (Fig. 1A) . To determine whether hnRNP-K alters translocation of AR to the nucleus, we evaluated the extent of accumulation of AR in cytoplasmic versus nuclear fractions after enforced expression of hnRNP-K. We found a similar lowering of AR in nuclei and cytosol (Fig. 1A, right panel) , indicating that hnRNP-K does not influence AR transit from cytoplasm to the nucleus, while it does alter steady-state levels of AR. Conversely, knockdown of endogenous hnRNP-K by RNA interference (Fig. 1B) increased AR levels, suggesting that endogenous hnRNP-K is conferring the same function as the overexpressed protein. HnRNP-K siRNA also attenuated the suppressive effect of HB-EGF on AR mRNA levels (Fig. 1C) , suggesting that hnRNP-K controls AR levels downstream from the EGFR.
In order to assess whether the effect of hnRNP-K on AR is confined to LNCaP cells, (ARnegative) HeLa cells were transiently co-transfected with hnRNP-K along with human AR expression constructs and the effect of enforced expression of hnRNP-K on AR levels was monitored. Our results showed a significant decrease of AR expression in the presence of hnRNP-K in the presence and absence of androgen (not shown), consistent with the findings in the LNCaP cell background. Post-transcriptional regulation of AR by hnRNP-K. The experiments with HeLa cells suggested that the effect on AR was unlikely to be a result of changes in transcription of AR mRNA. Consistent with this hypothesis, we observed no changes in AR mRNA following enforced expression of hnRNP-K in LNCaP cells (not shown). HnRNP-K over-expression also did not affect AR mRNA levels when cells were treated with the transcription inhibitor, actinomycin D, for up to 20 h (not shown). Actinomycin D similarly did not alter the observed hnRNP-K effects on AR protein levels (Fig. 1D ).
The selective mTOR inhibitor, rapamycin, increased AR expression in LNCaP cells, consistent with published results [1] (Fig. 2A) . HnRNP-K siRNA evoked a comparable, but not additive, effect on AR protein levels, suggesting that hnRNP-K may act upstream of mTOR ( Fig. 2A, right panel) . Rapamycin exerts regulatory effects on cap-dependent mRNAs. EGFR activation was previously shown to attenuate AR protein levels in a rapamycin-sensitive manner, at least partly through the AR mRNA 5'-UTR [1] . Thus, we analyzed the effect of enforced expression of hnRNP-K on a 570 nt fragment of the AR 5'-UTR, which contains several cis-acting elements and cap-and stem-loop secondary structures and was shown previously to be rapamycin-sensitive [1] . To do this, we used a luciferase plasmid system in which the 5'-UTR fragment regulates the CMV promoter and that reports effects on cap-dependent mRNA translation. Rapamycin induced luciferase expression from this plasmid construct ( These data strongly suggest that hnRNP-K exerts its attenuating effects on AR expression at the level of mRNA translation. Consistent with this interpretation, we verified the direct binding of hnRNP-K with AR 5`-UTR RNA corresponding to this same UTR region by RNA gel mobility shift in concert with purified GST-hnRNP-K (not shown), and also with endogenous AR mRNA in whole cells using immunoprecipitation/reverse transcription-PCR (Fig. 2B, right panel) . The inhibitory effect of hnRNP-K on expression driven by the AR 5`-UTR (Fig. 2B) does not require the AR, since similar findings were obtained in AR-negative COS cells (Fig. 2C, left panel) . Inspection of the 570 nt rapamycin-sensitive region in the AR 5'-UTR using the consensus sequence U(C)nA/U revealed two potential hnRNP-K binding sites at nt 412-417 (UCCCCA) and 476-480 (UCCCU). To evaluate whether either of these UC-rich regions mediates some or all of the inhibitory effects of hnRNP-K on the translation reporter, we generated single and double mutants within the rapamycin-sensitive fragment (Fig. 2D, left panel) (Fig. 2D, right panel) , confirming the involvement of the 412-417 site within the AR 5'-UTR in the regulatory effect we observed with hnRNP-K.
HnRNP-K inhibits translation of AR mRNA. HnRNP-K regulates translation of the L2 capsid protein of human papillomavirus type 16 by binding within the open reading frame of the coding region [2] . Inspection of the entire AR mRNA indicated that the message may harbor as many as 9 other potential hnRNP-K binding sites in the coding region and in the 3'-UTR (Table 1) suggesting the possibility that hnRNP-K may also regulate AR expression through one or more of these additional sites. To address this question, we examined the effect of hnRNP-K on translation of AR mRNA using a construct containing only the AR coding region, which contains 6 potential hnRNP-K binding sites (Table  1) .
AR was synthesized with a coupled transcription/translation system, using either [
35 S]methionine for radioactive detection or unlabeled methionine for Western blot identification. Addition of purified GSThnRNP-K dose-dependently decreased the synthesis of the 100 and 110 kDa translated products (Fig.  3) . In contrast, no translation inhibition was observed on the internal control luciferase mRNA (lower panels). Results with cold methionine (Fig. 3B) confirmed the identity of the translation products as AR by immunoblotting. In a complementary experiment, enforced expression of hnRNP-K in HeLa cells reduced the expression of AR expressed from the same hAR construct used in the coupled transcriptiontranslation experiments (not shown). These findings indicate that hnRNP-K employs one or more binding sites within the coding region in a manner that is functionally compatible with the single binding site we identified in the rapamycin-sensitive region of the 5'-UTR.
In an independent test of the ability of hnRNP-K to act as a regulator of AR translation, we probed the distribution of AR mRNA in polysomal fractions isolated from LNCaP cells under conditions where hnRNP-K expression was enforced. If hnRNP-K acts as an inhibitor of AR mRNA translation at the level of initiation, then its forced expression would result in the dissociation of AR mRNA from actively translating ribosomes and a re-partitioning of the mRNA toward the lighter fractions of the gradient. As indicated in Figure 3C (left and right panels), hnRNP-K had no such effect on the distribution of AR mRNA in gradient fractions, suggesting that the protein does not inhibit translation initiation of AR mRNA. HnRNP-K had no effect on the distribution of tubulin mRNA (Fig. 3C, bottom panels) , as expected. Next, we tested the possibility that the AR mRNA under conditions of enforced hnRNP-K expression was associated with translationally-inactive ribosomes, an event generally associated with a defect in peptide elongation. To test this, we used puromycin, which causes premature termination and release of all actively elongating mRNAs from polysomes. If an mRNA species is not being actively translated, puromycin will not be incorporated into the peptide chain and mRNA release from polysomes will not occur. In the absence of elevated hnRNP-K, puromycin caused a release of tubulin and AR mRNAs from the polysomal fractions (compare Fig. 3C left panel, with 3D left panel, particularly lanes 8-11 which contain AR and tubulin mRNAs associated with large polysomes). However, when hnRNP-K expression was enforced, AR mRNA was retained in heavy polysomal fractions, even after puromycin treatment (compare Fig. 3C and D) , indicating that hnRNP-K evokes a reduction in rate of AR mRNA chain elongation. HnRNP-K inhibits PSA promoter activity and LNCaP cell proliferation. In order to determine whether AR down-regulation by hnRNP-K has functional consequences in PCa cells, we assessed the effect of enforced hnRNP-K expression on the androgen-responsive human prostate-specific antigen (PSA) promoter, and on LNCaP cell growth. Androgen-induced activation of the reporter gene was strongly and dose-dependently inhibited by hnRNP-K (Fig. 4A) , indicating that hnRNP-K antagonizes androgenic signaling, consistent with a role as an AR antagonist. Similarly, hnRNP-K overexpression suppressed LNCaP cell proliferation (Fig. 4B) , a result consistent with the PSA promoter-reporter data. HnRNP-K expression in human prostate cancer. Multiple data sets in the Oncomine cancer profiling database (www.oncomine.org) indicate that hnRNP-K is expressed in human PCa. We analyzed a human PCa TMA containing benign prostate tissues, organ-confined cancers, and metastases [hormone naive (HN) and hormone (castration) resistant (HR)] using a monospecific anti hnRNP-K antibody. HnRNP-K was detected in the nucleus of the majority of benign and carcinoma samples at high levels, and expression was significantly increased in metastatic tumors in comparison with benign tissues and organ-confined tumors (p = 0.0001 and 0.0004, respectively) (Fig. 5A, left panel) , a trend that was maintained when HR metastases were compared with HN metastases (Fig. 5A, right panel) . Notably, hnRNP-K and AR levels were significantly inversely correlated in localized PCa specimens (p < 0.001) (Fig. 5B) . Finally, hnRNP-K was cytosolic and nuclear localized in organ-confined tumors, but cytosolic expression was significantly decreased in the metastases (Fig. 5C, D) . 
KEY RESEARCH ACCOMPLISHMENTS
• In year 1 we determined and reported the mechanism of regulation of AR expression by hnRNP-K
• Immunohistochemical analysis of a human PCa tissue microarray revealed an inverse correlation between hnRNP-K expression and AR protein levels in organ-confined prostate cancers and a substantial decline in cytoplasmic hnRNP-K in metastases, despite an overall increase in hnRNP-K levels in metastatic tumors. These findings are consistent with the possibility that the translational inhibitor mechanism we have identified is down-regulated with disease progression (i.e., cytoplasmic hnRNP-K is lost with progression).
• HnRNP-K is the first protein identified by any group that directly interacts with and regulates the AR translational apparatus. 
REPORTABLE OUTCOMES
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CONCLUSIONS
This study has identified the RNA binding protein hnRNP-K as a physiologically relevant regulator of the androgen receptor in prostate cancer cells. Notably, hnRNP-K is the first protein ever shown to be a direct regulator of androgen receptor translation, despite reports from more than ten years ago that the AR can be regulated at the translational level. We are very encouraged by our data set at present as we move into year 2 of the project.
